No Data
No Data
The TOPIX 250 index in the Tokyo Stock Exchange's Growth Market rebounded, with trading volume lower and the increase narrowing.
TOPIX Growth Market Index 851.07 +4.78 / Volume 0.2 billion 62.71 million shares / Trading value JPY 112.7 billion. TOPIX Growth Market 250 Index 660.90 +3.65 / Volume 0.1 billion 82.45 million shares / Trading value JPY 91.6 billion. Today's growth market saw increases in both the TOPIX Growth Market Index and TOPIX Growth Market 250 Index. Number of rising stocks was 317, number of falling stocks was 222, and unchanged stocks were 45. On the 22nd, the US stock market rebounded. The Dow rose 127.91 dollars (+0.
The TOPIX-250 Index fell for the first time in 5 days due to the decline in investor sentiment and the weak market for leading stocks.
The Tokyo Stock Exchange Growth Market Index was 883.91, down 6.52, with a volume of 0.25396 billion shares and a trading value of 151.1 billion yen. The Tokyo Stock Exchange Growth Market 250 Index was 690.17, down 4.94, with a volume of 0.02 billion 2.62 million shares and a trading value of 133 billion yen. Today's growth market, both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index, fell for the first time in five days. The number of rising stocks was 199, the number of falling stocks was 353, and unchanged was 30. The US stock market on the 17th was mixed. The Dow Jones Industrial Average was down 243.60.
Anges - EmendoBio presented their proprietary technology at a conference and won the poster award.
On the 11th, Anges <4563> announced that its subsidiary EmendoBio's proprietary technology was presented at a scientific conference and won the poster award. The company's researchers participated in the 9th Annual Meeting of the Japanese Genome Editing Society held at the Osaka City Central Public Hall from June 17th to 19th. The "Japanese Genome Editing Society" is held annually to report the latest knowledge and clinical and industrial applications of genome editing technology, and its scale is expanding year by year. During the conference, there were 30 presentations and 64 posters.
Medirex, HYUGA PRIMARY CARE, etc.
<205A> Logos Holdings Co., Ltd., Yuoichi Ikeda's shareholding ratio - % → 9.05%. Reporting obligation date: June 28, 2024. <205A> Logos Holdings Co., Ltd., Endeavor United Corporation's shareholding ratio - % → 53.86%. Reporting obligation date: June 28, 2024. <206A> Prism BioLab Co., Ltd., Yoshiichiro Nakashima's shareholding ratio - % → 5.29%. Reporting obligation.
Insider decrases its stake in AnGes(4563.JP) to 7.19%
On Jul 8, CANTOR FITZGERALD EUROPE submitted the Change Report to Ministry of Finance. The report shows that CANTOR FITZGERALD EUROPE decreased their holdings in $AnGes(4563.JP)$, with their joint sha
Change in the development and sales strategy of Anges - HGF gene therapy product "Collategene".
On the 24th, Anges announced a change in the development and sales strategy of its HGF gene therapy product "Collategene." The late-phase 2 clinical trial (February 2020-March 2023) for Collategene, targeting mild to moderate atherosclerosis with lower limb ulcers in the United States, has been completed with good results. Based on these results, the previous approval for severe patients only with conditional and time-limited approval will be temporarily withdrawn and will now be applicable to patients with various degrees of atherosclerosis.
No Data